<div id="readability-page-1"><p><span>Corcept Therapeutics (NASDAQ:CORT - Get Free Report)</span> was upgraded by stock analysts at Zacks Research from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p><ul><li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li></ul><p>Several other analysts have also issued reports on CORT. Truist Financial raised Corcept Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 26th. Wolfe Research raised shares of Corcept Therapeutics from an &#34;underperform&#34; rating to a &#34;peer perform&#34; rating in a research note on Thursday, March 26th. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday. Finally, HC Wainwright raised their price target on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a report on Monday. One analyst  has rated the stock with a Strong Buy rating, three have assigned  a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $74.67.</p><div><p><span></span><span>Get <strong>Corcept Therapeutics</strong> alerts:</span></p></div><p><b>View Our Latest Report on Corcept Therapeutics</b></p><h2>Corcept Therapeutics Stock Down 0.5%</h2><p>CORT opened at $51.37 on Monday. The business's fifty day simple moving average is $39.47 and its 200 day simple moving average is $54.18. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $91.00. The stock has a market cap of $5.51 billion, a PE ratio of 146.76 and a beta of 0.36. </p><p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $0.17 EPS.  As a group, equities analysts anticipate that  Corcept Therapeutics will post 0.35 earnings per share for the current year. </p><h2>Insider Activity</h2><p>In other Corcept Therapeutics news, Director G Leonard Baker, Jr. purchased 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the purchase, the director directly owned 1,146,631 shares of the company's stock, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares in the company, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 66,198 shares of company stock valued at $2,851,169. Company insiders own  20.70% of the company's stock. </p><h2>Institutional Investors Weigh In On Corcept Therapeutics</h2><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of  Corcept Therapeutics during the fourth quarter valued at about $25,000.  Advisory Services Network LLC purchased a new stake in  Corcept Therapeutics in the third quarter worth about $25,000.  Clearstead Advisors LLC boosted its position in  Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 193 shares in the last quarter.  Atlas Capital Advisors Inc. bought a new stake in  Corcept Therapeutics during the 4th quarter valued at approximately $31,000.  Finally, Hantz Financial Services Inc. grew its holdings in shares of  Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 524 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors. </p><h2>About Corcept Therapeutics</h2> (Get Free Report)<p>Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.  </p><p>The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.</p><h2>See Also</h2><ul><li>Five stocks we like better than Corcept Therapeutics</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Corcept Therapeutics Right Now?</h2><p>Before you consider Corcept Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.</p><p>While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CORT

LABU

<p>Zacks Research upgraded Corcept Therapeutics (NASDAQ:CORT) from a "strong sell" to a "hold" rating. Other analysts have also raised their ratings, with Truist Financial giving a "strong-buy" and Canaccord Genuity increasing the price target from $100 to $110. The stock opened at $51.37, with a market cap of $5.51 billion. Corcept reported a quarterly EPS of ($0.30), missing estimates, but revenue increased 4.9% year-over-year. Insider trading activity included a significant purchase by Director G Leonard Baker, Jr. and a sale by CEO Joseph K. Belanoff.</p>

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating